Sage Therapeutics, Inc. (SAGE): Price and Financial Metrics


Sage Therapeutics, Inc. (SAGE): $38.82

1.87 (+5.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SAGE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 455

in industry

SAGE POWR Grades


  • SAGE scores best on the Value dimension, with a Value rank ahead of 95.67% of US stocks.
  • The strongest trend for SAGE is in Quality, which has been heading up over the past 169 days.
  • SAGE ranks lowest in Growth; there it ranks in the 1st percentile.

SAGE Stock Summary

  • With a price/earnings ratio of 3.39, Sage Therapeutics Inc P/E ratio is greater than that of about only 3.1% of stocks in our set with positive earnings.
  • SAGE's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 5.62% of US stocks.
  • As for revenue growth, note that SAGE's revenue has grown 15,871.49% over the past 12 months; that beats the revenue growth of 99.9% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Sage Therapeutics Inc, a group of peers worth examining would be GMBL, MICT, MRNS, QURE, and BNTX.
  • Visit SAGE's SEC page to see the company's official filings. To visit the company's web site, go to www.sagerx.com.

SAGE Valuation Summary

  • In comparison to the median Healthcare stock, SAGE's price/earnings ratio is 88.77% lower, now standing at 4.1.
  • SAGE's price/sales ratio has moved NA NA over the prior 87 months.
  • Over the past 87 months, SAGE's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for SAGE.

Stock Date P/S P/B P/E EV/EBIT
SAGE 2021-08-31 2.4 1.4 4.1 3.3
SAGE 2021-08-30 2.4 1.4 4.0 3.2
SAGE 2021-08-27 2.4 1.4 4.0 3.2
SAGE 2021-08-26 2.3 1.3 3.8 3.0
SAGE 2021-08-25 2.3 1.3 3.8 3.1
SAGE 2021-08-24 2.3 1.3 3.8 3.1

SAGE Growth Metrics

    Its 3 year price growth rate is now at 389.27%.
  • Its 5 year price growth rate is now at 20.48%.
  • The 5 year cash and equivalents growth rate now stands at -32.67%.
SAGE's revenue has moved up $1,113,852,000 over the prior 67 months.

The table below shows SAGE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 1,113.852 730.29 641.715
2021-06-30 1,114.051 708.1 666.151
2021-03-31 1,113.497 691.885 637.049
2020-12-31 1,114.2 664.28 606.073
2020-09-30 6.974 -463.417 -537.475
2020-06-30 8.905 -501.103 -611.698

SAGE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SAGE has a Quality Grade of C, ranking ahead of 62.22% of graded US stocks.
  • SAGE's asset turnover comes in at 0.544 -- ranking 73rd of 681 Pharmaceutical Products stocks.
  • VTGN, SVRA, and SESN are the stocks whose asset turnover ratios are most correlated with SAGE.

The table below shows SAGE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.544 0.999 0.571
2021-06-30 0.637 0.999 0.746
2021-03-31 0.767 0.999 0.960
2020-12-31 0.954 0.999 1.092
2020-09-30 0.008 0.907 -0.813
2020-06-30 0.009 0.929 -0.814

SAGE Price Target

For more insight on analysts targets of SAGE, see our SAGE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $85.11 Average Broker Recommendation 1.66 (Moderate Buy)

SAGE Stock Price Chart Interactive Chart >

Price chart for SAGE

SAGE Price/Volume Stats

Current price $38.82 52-week high $88.51
Prev. close $36.95 52-week low $36.02
Day low $36.76 Volume 429,687
Day high $38.82 Avg. volume 473,203
50-day MA $40.40 Dividend yield N/A
200-day MA $50.39 Market Cap 2.29B

Sage Therapeutics, Inc. (SAGE) Company Bio


Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders. The company was founded in 2010 and is based in Cambridge, Massachusetts.


SAGE Latest News Stream


Event/Time News Detail
Loading, please wait...

SAGE Latest Social Stream


Loading social stream, please wait...

View Full SAGE Social Stream

Latest SAGE News From Around the Web

Below are the latest news stories about Sage Therapeutics Inc that investors may wish to consider to help them evaluate SAGE as an investment opportunity.

Asymmetry Capital Management, L.P. Buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, ...

Investment company Asymmetry Capital Management, L.P. (Current Portfolio) buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, AbbVie Inc, IQVIA Holdings Inc, Centene Corp, sells Alkermes PLC, Medtronic PLC, Insulet Corp, Hologic Inc, Sage Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Asymmetry Capital Management, L.P..

Yahoo | January 19, 2022

Analysts Are Bullish on Top Healthcare Stocks: SAGE Therapeutics (SAGE), Glaukos (GKOS)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SAGE Therapeutics (SAGE – Research Report) and Glaukos (GKOS – Research Report) with bullish sentiments. SAGE Therapeutics (SAGE) Needham analyst Ami Fadia maintained a Buy rating on SAGE Therapeutics today and set a price target of $85.00. The company's shares closed last Friday at $42.93, close to its 52-week low of $36.13. According to TipRanks.

Brian Anderson on TipRanks | January 18, 2022

SAGE Therapeutics Inc (SAGE): Hedge Funds Are Taking Some Chips Off The Table

The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30th. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]

Yahoo | January 12, 2022

Biogen defends Alzheimer's drug, highlights pipeline at J.P. Morgan conference

In a high-stakes presentation at the J.P. Morgan Healthcare conference, Biogen Inc. executives said they wanted to "improve the community's understanding" of Aduhelm but left less than 10 minutes to answer questions from investors and attendees.

Yahoo | January 10, 2022

Needham Thinks SAGE Therapeutics’ Stock is Going to Recover

In a report released today, Ami Fadia from Needham reiterated a Buy rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $85.00. The company's shares closed last Wednesday at $39.45, close to its 52-week low of $36.13. According to TipRanks.com, Fadia is a 1-star analyst with an average return of -2.3% and a 41.0% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Intra-Cellular Therapies, and Avadel Pharmaceuticals. Currently, the analyst consensus on SAGE Therapeutics is a Moderate Buy with an average price target of $64.80.

Howard Kim on TipRanks | January 6, 2022

Read More 'SAGE' Stories Here

SAGE Price Returns

1-mo -8.66%
3-mo -3.82%
6-mo -11.23%
1-year -51.03%
3-year -70.51%
5-year -18.19%
YTD -8.74%
2021 -50.83%
2020 19.84%
2019 -24.64%
2018 -41.84%
2017 222.58%

Continue Researching SAGE

Here are a few links from around the web to help you further your research on Sage Therapeutics Inc's stock as an investment opportunity:

Sage Therapeutics Inc (SAGE) Stock Price | Nasdaq
Sage Therapeutics Inc (SAGE) Stock Quote, History and News - Yahoo Finance
Sage Therapeutics Inc (SAGE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9208 seconds.